CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

oral co-trimoxazoleWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Role of Co-trimoxazole in Severe COVID-19 Patients

Coronavirus Disease 19 (COVID-19) is a global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Severe disease occurs in 15% of the cases with COVID-19 and may progress to critical disease in only 5% of the cases with a high risk of mortality. Critical disease may present as acute respiratory failure secondary to Acute Respiratory Distress Syndrome (ARDS) and is caused by the body's hyper-immune response to the virus in the form of a cytokine storm syndrome (CSS). There is currently no effective anti-viral treatment against SARS-CoV-2 and the mainstay of treatment is supportive. Co-trimoxazole (combination of trimethoprim and sulphamethoxazole in a 1:5) ratio is a Sulphur containing anti-folate bactericidal antibiotic indicated for the treatment of respiratory tract infections. It has been around for over 60 years and is inexpensive and readily available with a good safety profile. It has a rapid onset of action with excellent bioavailability and lung penetration. In addition to having antimicrobial properties co-trimoxazole have immunomodulatory and anti-inflammatory properties and may be a potential treatment option for cytokine storm syndrome mediated severe COVID-19. This open-label randomized controlled trial will be conducted in the department of medicine at Bangabandhu Sheikh Mujib Medical University (BSMMU), Anwar Khan Modern Medical college and Mughda Medical College Hospital (DMCH), Dhaka for a duration of 6 months following approval of this protocol. It will recruit at least 94 consecutive adults (18 years or older) patients with clinically suspected COVID-19 and severe illness as per WHO criteria. After taking informed written consent patients will be randomly assigned in a 1:1 ratio to either oral co-trimoxazole in addition to standard therapy or standard therapy alone. Baseline characteristics, changes in the physiological and biochemical parameters like (SpO2/FiO2 ratio, respiratory rate, body temperature and C - reactive protein), length of hospital stay, side effects of drugs, requirement for ventilatory support (non-invasive and invasive ventilation) and in-patient mortality between the two groups will be compared. Conclusion If the results from this clinical trial demonstrate the beneficial effects of co-trimoxazole in severe COVID-19 patients it could be used widely, thereby reducing the need for respiratory support and potentially saving thousands of lives in developing nations with limited resources where healthcare may be easily overwhelmed.

NCT04470531 Covid19 Severe COVID-19 Patients Drug: oral co-trimoxazole

Primary Outcomes

Description: Duration of hospital stay in days

Measure: Length of stay in hospital (in days)

Time: 14 days

Description: % of patients died after enrollment

Measure: In-patient mortality

Time: 14 days

Secondary Outcomes

Description: ratio of Saturation of oxygen in % and Fraction of inspired oxygen

Measure: SpO2/FiO2 ratio

Time: Day 1,2,3,4 and 5

Description: Respiratory rate per minute

Measure: respiratory rate

Time: Day 1,2,3,4 and 5

Description: CRP level in mg/litre

Measure: C-reactive Protein

Time: Day 1,2,3,4 and 5

Description: Temperature in degree Fahrenheit

Measure: Fever

Time: Day 1,2,3,4 and 5

Description: Requirement of ventilator support in hours

Measure: Ventilator support

Time: 14 days

Description: % of patients developed early reaction like fever, rash, abdominal pain, urticaria, vomiting, wheezing, chest tightness

Measure: Proportion of drug adverse reaction

Time: 24 hours

No related HPO nodes (Using clinical trials)